A Phase 2 interventional study of Pirfenidone and Placebo in Lung Diseases, Interstitial, sponsored by Hoffmann-La Roche. Completed at 66 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-01-13.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pirfenidone in Lung Diseases, Interstitial — 1 open to participants now, 2 under way, none of them phase 3. pirfenidone · Lung Diseases, Interstitial.
Among the 13 studies testing pirfenidone in Lung Diseases, Interstitial, this one has the largest enrollment, is one of 4 that started in 2017, is one of 8 in phase 2, and was the 5th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →1 of the 13 studies testing pirfenidone in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 18+
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2017.
This study's enrollment of 253 is above the median of 60 across 385 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 120 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 3 studies filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing pirfenidone in Lung Diseases, Interstitial, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).
Study participants will be randomised to receive 801 mg pirfenidone or placebo three times daily for 24 weeks. The efficacy of pirfenidone versus placebo will be assessed by daily measurement of forced vital capacity using a handheld spirometer over the treatment period. Additionally, the study will assess the efficacy and safety of pirfenidone with and without concomitant mycophenolate mofetil treatment and in study participants with or without interstitial pneumonia with autoimmune features (IPAF). All study participants who attend the follow-up visit at Week 28 will be offered the opportunity to receive open-label pirfenidone within the trial protocol. In order to maintain blinding of the controlled period of the study, all study participants will discontinue treatment by Week 24 and return for a follow-up visit 4 weeks later. Study participants eligible to participate in the single-arm 12-month extension will be initiated on open-label pirfenidone during this visit (re-starting the dose titration from one capsule three times daily [TID]). During the long-term extension period, study participants will be monitored for safety, initially at monthly visits during the first 6 months and thereafter approximately every 3 months. A final follow-up visit will take place 4 weeks after the last dose of pirfenidone is taken.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
Drug: Pirfenidone
Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
Drug: Placebo
Pirfenidone 267 mg capsules three times in a day.
Matching placebo capsules three times in a day.
Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period
Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.
Time frame: Up to Week 24
Change in Percent Predicted FVC
FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
Time frame: Baseline (Day 1) to Week 24
Change in FVC
FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
Time frame: Baseline (Day 1) to Week 24
Categorical Change in FVC of >5%
Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
Time frame: Baseline (Day 1) to Week 24
Categorical Change in FVC of >10%
Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
Time frame: Baseline (Day 1) to Week 24
Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)
The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.
Time frame: Baseline (Day 1) to Week 24
Change in 6-minute Walk Distance (6MWD)
Comparison of 6-minute walk distance before beginning and after completing study therapy.
Time frame: Baseline (Day 1) to Week 24
Change in University of California, San Diego-Shortness of Breath Questionnaire Score
University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.
Time frame: Baseline (Day 1) to Week 24
Change in Score in Leicester Cough Questionnaire Score
The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.
Time frame: Baseline (Day 1) to Week 24
Change in Cough Visual Analog Scale (VAS) Score
Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.
Time frame: Baseline (Day 1) to Week 24
Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)
The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.
Time frame: Baseline (Day 1) to Week 24
Number of Participants With Non-elective Hospitalization, Both Respiratory and All Cause
Participants with non-elective hospitalization are reported.
Time frame: Baseline (Day 1) to Week 24
Percentage of Participants With Investigator-reported Acute Exacerbations
Percentage of participants with acute exacerbation arereported.
Time frame: Baseline (Day 1) to Week 24
Time to First Investigator-reported Acute Exacerbations
Time to first investigator reported acute exacerbations from start of treatment are reported.
Time frame: Baseline (Day 1) to Week 24
Progression-free Survival (PFS)
PFS is defined as the time to the first occurrence of a \>10% absolute decline in percent predicted FVC, a \>50 m decline of 6MWD, or death.
Time frame: Baseline (Day 1) to Week 24
Progression-free Survival (PFS)
PFS is defined as the time to the first occurrence of a \>10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.
Time frame: Baseline (Day 1) to Week 24
Time to Death From Any Cause
Time to first documented death from start of treatment is reported.
Time frame: Baseline (Day 1) to Week 24
Time to Death From Respiratory Diseases
Time to first documented death due to respiratory diseases from start of treatment will be reported.
Time frame: Baseline (Day 1) to Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline (Day 1) to Week 28
Number of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period
Number of participants with dose reduction and treatment interruptions are reported.
Time frame: From administration of the first dose of study drug to Week 24
Number of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up
Number of participants with dose reduction and treatment interruptions are reported.
Time frame: From the Follow-up Visit at Week 28 through the follow-up period of 12 Months
Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period
Number of participants withdrawn from trial treatment or trial discontinuations are reported.
Time frame: Baseline (Day 1) to Week 24
Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up
Number of participants withdrawn from trial treatment or trial discontinuations are reported.
Time frame: From the Follow-up Visit at Week 28 through the follow-up period of 12 Months
| Milestone | Pirfenidone | Placebo | Open-Label Treatment (Pirfenidone) | Open-Label Treatment (Placebo) |
|---|---|---|---|---|
| Started | 127 | 126 | 0 | 0 |
| Completed | 94 | 110 | 0 | 0 |
| Not completed | 33 | 16 | 0 | 0 |
| Withdrew: Adverse event | 19 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 3 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 4 | 0 | 0 |
| Withdrew: Lung transplantation | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 |
| Withdrew: Randomization error | 0 | 2 | 0 | 0 |
| Withdrew: Non-compliance with protocol procedure | 1 | 1 | 0 | 0 |
| Milestone | Pirfenidone | Placebo | Open-Label Treatment (Pirfenidone) | Open-Label Treatment (Placebo) |
|---|---|---|---|---|
| Started | 0 | 0 | 94 | 110 |
| Completed | 0 | 0 | 75 | 84 |
| Not completed | 0 | 0 | 19 | 26 |
| Withdrew: Adverse event | 0 | 0 | 5 | 12 |
| Withdrew: Death | 0 | 0 | 7 | 9 |
| Withdrew: Lung transplantation | 0 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 2 |
| Withdrew: Due to hospitalization | 0 | 0 | 0 | 1 |
Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.
| milliliter (mL) | Pirfenidone | Placebo |
|---|---|---|
| Primary Analysis in 2019 | -17.9 (-311.7 to 275.9) | 116.6 (-451.9 to 685.2) |
| Final Analysis in 2020 | -90.3 (-157.0 to -23.7) | 125.6 (-458.4 to 709.6) |
FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
| Percent predicted (%) | Pirfenidone | Placebo |
|---|---|---|
| Baseline (Day 1) | 73.95 ± 18.815 | 73.95 ± 19.974 |
| Week 4 | 74.04 ± 19.009 | 74.55 ± 21.223 |
| Week 8 | 73.98 ± 19.324 | 73.50 ± 20.168 |
| Week 12 | 73.96 ± 19.493 | 73.91 ± 20.856 |
| Week 16 | 74.56 ± 20.299 | 72.65 ± 22.479 |
| Week 20 | 73.94 ± 21.000 | 71.99 ± 21.673 |
| Week 24 | 72.95 ± 20.819 | 73.55 ± 22.383 |
FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
| Liter (L) | Pirfenidone | Placebo |
|---|---|---|
| Baseline | 2.36 ± 0.793 | 2.38 ± 0.747 |
| Week 4 | 2.37 ± 0.818 | 2.37 ± 0.786 |
| Week 8 | 2.37 ± 0.822 | 2.36 ± 0.816 |
| Week 12 | 2.37 ± 0.820 | 2.35 ± 0.773 |
| Week 16 | 2.41 ± 0.860 | 2.31 ± 0.782 |
| Week 20 | 2.40 ± 0.866 | 2.30 ± 0.796 |
| Week 24 | 2.37 ± 0.863 | 2.34 ± 0.773 |
Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
| Number of Participants | Pirfenidone | Placebo |
|---|---|---|
| Primary Analysis in 2019 | 47 | 74 |
| Final Analysis in 2020 | 47 | 73 |
Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.
| Number of Participants | Pirfenidone | Placebo |
|---|---|---|
| Primary Analysis in 2019 | 18 | 34 |
| Final Analysis in 2020 | 18 | 33 |
The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.
| % predicted | Pirfenidone | Placebo |
|---|---|---|
| Baseline (Day 1) | 46.19 ± 12.403 | 49.57 ± 13.931 |
| Change from Baseline at Week 12 (Primary Analysis in 2019) | -0.52 ± 6.193 | -0.56 ± 8.807 |
| Change from Baseline at Week 24 (Primary Analysis in 2019) | -0.65 ± 7.113 | -2.47 ± 8.833 |
| Change from Baseline at Week 12 (Final Analysis in 2020) | -0.52 ± 6.193 | -0.89 ± 9.407 |
| Change from Baseline at Week 24 (Final Analysis in 2020) | -0.65 ± 7.113 | -2.48 ± 8.893 |
Comparison of 6-minute walk distance before beginning and after completing study therapy.
| meter (m) | Pirfenidone | Placebo |
|---|---|---|
| Baseline | 391.6 ± 114.93 | 394.0 ± 108.09 |
| Change from Baseline at Week 12 | -14.8 ± 66.23 | -7.7 ± 57.60 |
| Change from Baseline at Week 24 | -2.0 ± 68.11 | -26.7 ± 79.32 |
University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.
| Scores on a Scale | Pirfenidone | Placebo |
|---|---|---|
| Baseline | 44.17 ± 25.204 | 48.89 ± 23.441 |
| Change from Baseline at Week 12 | 1.47 ± 19.707 | 2.24 ± 18.617 |
| Change from Baseline at Week 24 | 5.21 ± 18.701 | 5.30 ± 22.078 |
The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.
| Scores on a Scale | Pirfenidone | Placebo |
|---|---|---|
| Baseline | 16.13 ± 3.711 | 15.15 ± 3.928 |
| Change from Baseline at Week 12 (Primary Analysis in 2019) | 0.35 ± 2.903 | -0.23 ± 3.654 |
| Change from Baseline at Week 24 (Primary Analysis in 2019) | 0.36 ± 2.889 | 0.04 ± 3.702 |
| Change from Baseline at Week 12 (Final Analysis in 2020) | 0.35 ± 2.903 | -0.23 ± 3.654 |
| Change from Baseline at Week 24 (Final Analysis in 2020) | 0.35 ± 2.884 | 0.04 ± 3.702 |
Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.
| millimeter (mm) | Pirfenidone | Placebo |
|---|---|---|
| Baseline | 35.60 ± 27.497 | 37.18 ± 26.270 |
| Change from Baseline at Week 12 | -4.33 ± 20.017 | 3.32 ± 26.429 |
| Change from Baseline at Week 24 | -2.52 ± 26.720 | 0.78 ± 30.121 |
The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.
| Scores of a Scale | Pirfenidone | Placebo |
|---|---|---|
| Symptoms sub-score - Baseline | 49.28 ± 21.687 | 53.10 ± 21.450 |
| Change from Baseline in Symptoms sub-score at Week 12 | -2.60 ± 19.173 | 0.86 ± 16.212 |
| Change from Baseline in Symptoms sub-score at Week 24 | -1.69 ± 19.186 | -0.66 ± 15.407 |
| Activities sub-score - Baseline | 63.93 ± 20.388 | 66.96 ± 18.615 |
| Change from Baseline in Activities sub-score at Week 12 | 1.17 ± 13.376 | 1.13 ± 13.704 |
| Change from Baseline in Activities sub-score at Week 24 | 1.25 ± 14.629 | 2.22 ± 13.110 |
| Impacts sub-score - Baseline | 37.12 ± 20.484 | 41.47 ± 20.520 |
| Change from Baseline in Impacts sub-score at Week 12 | 0.29 ± 16.826 | 0.33 ± 13.888 |
| Change from Baseline in Impacts sub-score at Week 24 | -0.18 ± 13.884 | 1.07 ± 17.539 |
| Total score - Baseline | 47.37 ± 18.465 | 51.46 ± 17.699 |
| Change from Baseline in Total score at Week 12 | -0.17 ± 13.633 | 0.53 ± 11.724 |
| Change from Baseline in Total score at Week 24 | 0.05 ± 12.549 | 0.85 ± 13.383 |
Participants with non-elective hospitalization are reported.
| Number of Participants | Pirfenidone | Placebo |
|---|---|---|
| All-cause hospitalization | 16 | 13 |
| Respiratory-related hospitalization | 5 | 5 |
Percentage of participants with acute exacerbation arereported.
| Percentage of Participants | Pirfenidone | Placebo |
|---|---|---|
| Percentage of Participants With Investigator-reported Acute Exacerbations | 3.9 | 5.6 |
Time to first investigator reported acute exacerbations from start of treatment are reported.
| Weeks | Pirfenidone | Placebo |
|---|---|---|
| Time to First Investigator-reported Acute Exacerbations | NA (NA to NA) | NA (NA to NA) |
PFS is defined as the time to the first occurrence of a \>10% absolute decline in percent predicted FVC, a \>50 m decline of 6MWD, or death.
| Week | Pirfenidone | Placebo |
|---|---|---|
| Progression-free Survival (PFS) | 25.14 (24.14 to NA) | 24.71 (24.14 to NA) |
PFS is defined as the time to the first occurrence of a \>10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.
| Week | Pirfenidone | Placebo |
|---|---|---|
| Progression-free Survival (PFS) | NA (24.86 to NA) | NA (24.14 to NA) |
Time to first documented death from start of treatment is reported.
| Week | Pirfenidone | Placebo |
|---|---|---|
| Time to Death From Any Cause | NA (NA to NA) | NA (NA to NA) |
Time to first documented death due to respiratory diseases from start of treatment will be reported.
| Week | Pirfenidone | Placebo |
|---|---|---|
| Time to Death From Respiratory Diseases | NA (NA to NA) | NA (NA to NA) |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Participants | Pirfenidone | Placebo |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 120 | 101 |
Number of participants with dose reduction and treatment interruptions are reported.
| Number of Participants | Pirfenidone | Placebo |
|---|---|---|
| Participants with at least one dose modification | 51 | 34 |
| Participants with at least one dose interruption | 40 | 12 |
Number of participants with dose reduction and treatment interruptions are reported.
| Number of Participants | Open-Label Treatment (Pirfenidone) | Open-Label Treatment (Placebo) |
|---|---|---|
| Participants with at least one dose modification | 41 | 60 |
| Participants with at least one dose interruption | 24 | 34 |
Number of participants withdrawn from trial treatment or trial discontinuations are reported.
| Number of Participants | Pirfenidone | Placebo |
|---|---|---|
| Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period | 25 | 12 |
Number of participants withdrawn from trial treatment or trial discontinuations are reported.
| Number of Participants | Open-Label Treatment (Pirfenidone) | Open-Label Treatment (Placebo) |
|---|---|---|
| Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up | 19 | 26 |
Collected over Baseline (Day 1) to Week 28 in the double-blind period From the Follow-up Visit at Week 28 through the follow-up period of 12 Months in the open-label treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pirfenidone | 4/127 (3.1%) | 18/127 (14.2%) | 107/127 (84.3%) |
| Placebo | 7/124 (5.6%) | 20/124 (16.1%) | 81/124 (65.3%) |
| Open-Label Treatment (Pirfenidone) | 7/94 (7.4%) | 26/94 (27.7%) | 64/94 (68.1%) |
| Open-Label Treatment (Placebo) | 9/110 (8.2%) | 27/110 (24.5%) | 86/110 (78.2%) |
| Event | Pirfenidone | Placebo | Open-Label Treatment (Pirfenidone) | Open-Label Treatment (Placebo) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/127 | 3/124 | 2/94 | 6/110 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 2/127 | 4/124 | 5/94 | 3/110 |
| Lower respiratory tract infectionInfections and infestations | 1/127 | 1/124 | 1/94 | 4/110 |
| Atrial fibrillationCardiac disorders | 0/127 | 1/124 | 3/94 | 0/110 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/127 | 2/124 | 2/94 | 3/110 |
| Cardiac failure congestiveCardiac disorders | 1/127 | 0/124 | 2/94 | 1/110 |
| Respiratory tract infectionInfections and infestations | 1/127 | 0/124 | 2/94 | 0/110 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/127 | 0/124 | 2/94 | 0/110 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 0/127 | 0/124 | 2/94 | 1/110 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/127 | 0/124 | 2/94 | 0/110 |
| Event | Pirfenidone | Placebo | Open-Label Treatment (Pirfenidone) | Open-Label Treatment (Placebo) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 40/127 | 9/124 | 15/94 | 30/110 |
| DiarrhoeaGastrointestinal disorders | 23/127 | 23/124 | 9/94 | 15/110 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/127 | 22/124 | 9/94 | 8/110 |
| FatigueGeneral disorders | 21/127 | 19/124 | 5/94 | 12/110 |
| VomitingGastrointestinal disorders | 14/127 | 6/124 | 4/94 | 18/110 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/127 | 16/124 | 10/94 | 9/110 |
| RashSkin and subcutaneous tissue disorders | 9/127 | 7/124 | 8/94 | 16/110 |
| Decreased appetiteMetabolism and nutrition disorders | 18/127 | 11/124 | 7/94 | 13/110 |
| DyspepsiaGastrointestinal disorders | 17/127 | 7/124 | 5/94 | 8/110 |
| Lower respiratory tract infectionInfections and infestations | 8/127 | 13/124 | 9/94 | 14/110 |
| Age, Continuous(Years) | Pirfenidone | Placebo | Total |
|---|---|---|---|
| Mean | 68.0 ± 10.1 | 67.7 ± 9.2 | 67.8 ± 9.6 |
| Sex: Female, Male(Participants) | Pirfenidone | Placebo | Total |
|---|---|---|---|
| Female | 57 | 57 | 114 |
| Male | 70 | 69 | 139 |
| Race/Ethnicity, Customized(Participants) | Pirfenidone | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 16 |
| Not Hispanic or Latino | 115 | 112 | 227 |
| Not reported | 5 | 5 | 10 |
| Race/Ethnicity, Customized(Participants) | Pirfenidone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 1 | 0 | 1 |
| Asian | 5 | 0 | 5 |
| Black or African American | 1 | 2 | 3 |
| Other | 0 | 1 | 1 |
| White | 120 | 123 | 243 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2017 to primary completion in Nov 2018, 18 months.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 71. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone